Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.53 |
| ▸ | CNR2 | P34972 | 10/20 | 0.53 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10950386 | 0.86 | KDM4E (0.50) | KEAP1NFE2L2CNR2TAS2R14CNR1 | |
| SCHEMBL10592552 | 0.84 | CA12 (0.53) | KEAP1NFE2L2CNR2TAS2R14CNR1 | |
| SCHEMBL28783481 | 0.80 | CA12 (0.57) | POLBALDH1A1CA12CA9 | |
| SCHEMBL28340795 | 0.80 | KEAP1 (0.49) | KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL7014542 | 0.78 | CNR2 (0.68) | CNR2TAS2R14CNR1POLBALDH1A1 | |
| SCHEMBL15958717 | 0.77 | KEAP1 (0.59) | KEAP1NFE2L2CNR2TAS2R14POLB | |
| SCHEMBL7014895 | 0.77 | KDM4E (0.41) | KEAP1NFE2L2CNR2TAS2R14CNR1 | |
| SCHEMBL6966682 | 0.77 | POLB (0.62) | CNR2TAS2R14CNR1POLB | |
| SCHEMBL9972493 | 0.76 | KEAP1 (0.62) | KEAP1NFE2L2CNR2TAS2R14CNR1 | |
| SCHEMBL22022745 | 0.76 | TAS2R14 (0.43) | CNR2TAS2R14POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254675-B2 | Process for preparation of grapiprant | CADILA HEALTHCARE LIMITED (IN) | 2022-02-22 | — | — | US | disclosed |
| US-20210347776-A1 | PROCESS FOR PREPARATION OF GRAPIPRANT | CADILA HEALTHCARE LIMITED (IN) | 2021-11-11 | — | — | US | disclosed |
| US-20210079000-A1 | PROCESS FOR PREPARATION OF GRAPIPRANT | CADILA HEALTHCARE LIMITED (IN) | 2021-03-18 | — | — | US | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347776-A1 | PROCESS FOR PREPARATION OF GRAPIPRANT | ADCYAP1R1, GANC, DRD4 | KEAP1 4376/4885NFE2L2 3800/4885CNR2 547/4885 |
| US-11254675-B2 | Process for preparation of grapiprant | ADCYAP1R1, GANC, DRD4 | KEAP1 4376/4885NFE2L2 3800/4885CNR2 547/4885 |
| US-20210079000-A1 | PROCESS FOR PREPARATION OF GRAPIPRANT | ADCYAP1R1, GANC, DRD4 | KEAP1 4376/4885NFE2L2 3800/4885CNR2 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.